医疗设备板块呈现深度调整态势，全板块营业收入同比下滑4.1%，归母净利润与扣非归母净利润分别 大幅收缩35.5%和38.8%。行业压力主要源于医疗设备采购合规门槛提升叠加设备更新政策落地延迟， 致使医疗机构采购节奏放缓，全年招标总量同比缩减。尽管四季度招投标活动出现边际改善，但渠道库 存消化与收入确认周期因素仍对部分企业形成短期业绩压制。市场分化格局凸显，多数企业面临收入下 滑困境。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年，中国医疗器械行业在政策调整、市场需求波动与全球供应链重构的多重挑战中艰难企稳，全年 收入增速转正至0.78%，但利润端分化显著。进入2025年，行业开局再度遇冷，Q1营收、归母净利润、 扣非净利润同比下滑6.87%、12.17%、17.42%。医疗设备招标滞后、IVD集采冲击及高值耗材需求波动 成为主因。 分板块来看，2024年高值耗材板块收入增长13.42%，利润增速超收入端，归母净利润、扣非归母净利 润增速分别为14.86%、17.37%。进一步拆分，细分领域企业表现分化显著。其中，南微医学、安杰思 等消化介入类企业收入增速平稳但利润逐季承 ...

Company Overview - Aohua Endoscopy's closing price on May 8 was 47.23 yuan, down 5.50%, with a latest price-to-book ratio of 4.83 and a total market capitalization of 6.36 billion yuan [1] - As of March 31, 2025, Aohua Endoscopy had 4,022 shareholders, a decrease of 469 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes the research, production, and sales of electronic endoscopy equipment and endoscopic surgical consumables [1] Financial Performance - In the latest quarterly report for Q1 2025, Aohua Endoscopy reported revenue of 124 million yuan, a year-on-year decrease of 26.92% [1] - The net profit for the same period was -28,791,459.68 yuan, representing a year-on-year decline of 1,143.36% [1] - The sales gross margin stood at 66.36% [1] Industry Comparison - Aohua Endoscopy's PE (TTM) is -603.51, while the industry average is 49.20, indicating a significant underperformance compared to peers [2] - The company's market capitalization of 6.36 billion yuan is lower than the industry median of 4.73 billion yuan [2] - Other companies in the industry show varying PE ratios, with some like Tianyi Medical at -1,748.07 and Nuo Wei Zhan at -418.55, indicating a challenging environment for medical device companies [2]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-034 上海澳华内镜股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 8 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 113 | | --- | --- | | 普通股股东人数 | 113 | | 2、出席会议的股东所持有的表决权数量 | 54,032,705 | | 普通股股东所持有表决权数量 | 54,032,705 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 40.8823 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 40.8823 | ...

Yin Chena Road Middle 上海市通力律师事务所关于上海澳华内镜股份有限公司 2024 年年度股东大会的法律意见书 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司"）的委托,指派本所茹秋乐律师、俞挺律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》 等法律法规和规范性文件(以下统称"法律法规")及《上海澳华内镜股份有限公司章 程》(以下简称"公司章程")的规定就公司 2024 年年度股东大会(以下简称"本次 股东大会"）相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.40% increase over the past month and a 0.19% increase over the past three months, while it has decreased by 0.01% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.76%), United Imaging (10.54%), Aibo Medical (7.72%), Yirui Technology (6.34%), Shengxiang Biology (5.03%), Nanwei Medical (5.02%), Xinmai Medical (4.57%), Haier Biomedical (4.39%), Yahui Long (3.59%), and Aohua Endoscopy (3.38%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - The industry composition of the index holdings includes 46.02% in medical consumables, 33.17% in medical devices, and 20.81% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which are fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be processed according to the calculation and maintenance guidelines [2]

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the gastrointestinal endoscopy industry, specifically focusing on the upcoming launch of the X1 endoscope by Olympus, which holds over 70% market share in the global soft endoscope market [1][1]. Core Insights and Arguments - The launch of the X1 endoscope is anticipated to create a new growth cycle in the gastrointestinal endoscopy sector, with hospitals potentially delaying procurement of gastrointestinal endoscopes until the X1 is available [1][1]. - After the X1's launch, hospitals are expected to engage in concentrated purchasing, leading to a noticeable increase in quarterly revenue growth year-on-year within a year of the product's release [1][1]. - The domestic soft endoscope market is expected to face pressure in 2024 due to reduced bidding scale from policy factors and the fact that only the main unit of the X1 has been approved in China, causing some hospitals to postpone their purchases [1][1]. Future Expectations - The X1 endoscope is projected to be launched in China by the end of this year or early next year, which, combined with favorable policy changes and a prolonged destocking period for soft endoscope companies, may lead to a significant release of demand and improvement in company performance [2][2]. - The technological level of domestic soft endoscopes is continuously improving, gaining recognition from high-level domestic hospitals and initial acceptance in overseas markets. This positions domestic manufacturers to benefit from the industry growth driven by the X1 [3][3]. Investment Recommendations - Companies to watch include Aohua Endoscopy and Kaili Medical, which may benefit from the anticipated market changes and growth opportunities [4][4].

关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/6 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 249.91万股 | | 累计已回购股数占总股本比例 | 1.86% | | 累计已回购金额 | 9,998.69万元 | | 实际回购价格区间 | 36.98元/股~41.99元/股 | 一、回购股份的基本情况 证券代码：688212 证券简称：澳华内镜 公告编号：2025-033 上海澳华内镜股份有限公司 上海澳华内镜股份有限公司（以下简称"公司"）于 2025 年 1 月 3 日召开了 第二届董事会第十六次会议审议通过了《关于以集中竞价交易方式回购公司 ...

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has experienced a significant stock price increase of 7.98%, closing at 48.01 yuan, despite reporting a substantial decline in revenue and net profit in the latest quarterly report [1] - As of the first quarter of 2025, Aohua Endoscopy has 30 institutional investors holding a total of 24.937 million shares, with a market value of 1.064 billion yuan [1] - The company specializes in the research, production, and sales of electronic endoscopy equipment and related medical consumables, with a primary focus on endoscopy devices and services [1] Group 2 - In the first quarter of 2025, Aohua Endoscopy reported an operating revenue of 124 million yuan, a year-on-year decrease of 26.92%, and a net profit loss of approximately 28.79 million yuan, reflecting a year-on-year decline of 1143.36% [1] - The company's gross profit margin stands at 66.36% [1] - Aohua Endoscopy's current price-to-earnings ratio (PE) is significantly negative at -613.48, while the industry average PE is 48.90 [2]

华创医疗器械随笔系列11 证券研究报告 证 券 研 究 报 告 | 医药生物 | 2025年5月6日 X1镜体即将国内上市，消化内镜行业迎来新增长周期 华创医药首席分析师 郑辰 华创医药高级分析师 李婵娟 联系人：张良龙 执业编号：S0360520110002 邮箱： zhengchen@hcyjs.com 执业编号：S0360520110004 邮箱： lichanjuan@hcyjs.com 执业编号：S0360123110010 邮箱： zhanglianglong@hcyjs.com 本报告由华创证券有限责任公司编制 卖的出价或询价。本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 请仔细阅读PPT后部分的分析师声明及免责声明。 @2021 华创 版权所有 摘要 证监会审核华创证券投资咨询业务资格批文号：证监许可（2009）1210 号 2 • 奥林巴斯新一代X1产品迭代导致各区域软镜市场波动。奥林巴斯占据全球胃肠镜市场的70%左右份额，其内窥镜解决方案 （ESD）板块收入变化可表征软镜行业波动。时隔八年，奥林巴斯的新一代产品X1系统上市后迅速放量，在当地的X1上市之前， 院方可能会刻 ...

Core Viewpoint - The digestive endoscopy industry is expected to enter a new growth cycle with the launch of Olympus's X1 endoscope system, which will significantly impact the soft endoscope market in various regions [3][20]. Group 1: Olympus X1 Product Launch and Market Impact - The launch of Olympus's new generation X1 system has led to fluctuations in the soft endoscope market across different regions, as hospitals may delay procurement until the new product is available [3][11]. - The X1 system, which integrates advanced imaging technologies and ergonomic design, is anticipated to drive a significant increase in demand for soft endoscopes once fully launched in China [7][10]. - The X1 system's revenue contribution to Olympus's gastrointestinal business has increased from approximately 10% in Q3 2021 to around 30% by Q1 2024, indicating strong market acceptance [10][11]. Group 2: Domestic Market Challenges and Future Outlook - The domestic soft endoscope market is under pressure in 2024 due to factors such as anti-corruption measures affecting procurement and delays in equipment updates, leading to a projected 21.1% decline in the medical equipment bidding market [13][17]. - The X1 endoscope's main unit has been approved in China, but the accompanying endoscope is still pending approval, causing hospitals to postpone purchases [13][17]. - It is expected that the X1 endoscope will be fully launched by the end of this year or early next year, which could lead to a concentrated release of demand in the domestic market [17][18]. Group 3: Growth of Domestic Manufacturers - Domestic manufacturers like Aohua and Kaili Medical are expected to benefit from the industry growth driven by the X1 system, as their product quality continues to improve and gain recognition in high-tier hospitals [24][27]. - The domestic soft endoscope market's localization rate has increased from less than 15% in 2021 to over 35% by Q3 2024, indicating a growing acceptance of domestic products [25][27]. - Aohua's AQ-300 and Kaili's HD-580 have been recognized in major hospitals, and their sales are expected to increase as the market recovers [24][32].